<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $26.7 Million and EPS Loss of $1.74
Jasper Therapeutics Inc. has reported its financial results for the second quarter of 2025. The company, focused on developing briquilimab for mast cell-driven diseases, announced a net loss of $26.7 million for the three months ending June 30, 2025. This translates to a net loss per share attributable to common stockholders of $1.74. The research and development expenses for this period were $21.2 million, while general and administrative expenses amounted to $5.9 million. Jasper's cash and cash equivalents totaled $39.5 million as of June 30, 2025. In a significant operational update, Jasper has decided to halt its non-mast cell focused clinical and preclinical programs, including the SCID clinical program, to concentrate fully on the development of briquilimab. Enrollment in the ETESIAN study in asthma has been paused, with further data and decisions expected after the investigation into specific BEACON study cohorts concludes in the latter half of 2025. The company also plans to redose patients and enroll additional participants in the BEACON study cohorts and aims to report related data by late 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-075678), on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.